Anti-PD1 antibody enhances the anti-tumor efficacy of MUC1-MBP fusion protein vaccine via increasing Th1, Tc1 activity and decreasing the proportion of MDSC in the B16-MUC1 melanoma mouse model.
Sign Up to like & getrecommendations! Published in 2021 at "International immunopharmacology"
DOI: 10.1016/j.intimp.2021.108173
Abstract: In previous studies, we have obtained a notable anti-tumor efficacy of the recombinant MUC1-MBP vaccine in the process of mouse B16-MUC1 melanoma treatment. However, the tumor cannot be eliminated completely. We found that the tumor… read more here.
Keywords: muc1; tumor efficacy; anti tumor; muc1 mbp ... See more keywords